Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative

symbol logo$STOK Q3 '26 Earnings Results & Recap

• Reported GAAP EPS of -$1.08 down -66.15% YoY • Reported revenue of $11.26M up 5.93% YoY • Stoke Therapeutics said its $358.8M in cash, cash equivalents and marketable securities as of September 30, 2026 is expected to fund operations into early 2028.

Price since post

Full Details

Advertisement|Remove ads.